Looking to add a small-cap health-care stock to your portfolio? You might want to carefully consider the recent performance and future prospects of diagnostic-test-kit maker Meridian Bioscience
Overall, the medical-diagnostics industry continues to sizzle. In January, Abbott Laboratories
Meridian Bioscience isn't looking too bad, either. Diluted earnings per share for the second quarter grew by 22% on a 14% increase in net sales versus the year-ago quarter. The company also confirmed its full-year guidance of diluted EPS in a range of $0.83 to $0.87 and declared a regular quarterly cash dividend of $0.16 per share -- a 39% increase in the regular quarterly rate over the prior fiscal year.
What's driving this growth at Meridian? Is it sustainable? In terms of growth drivers, Q2 earnings were fueled by greater sales of the company's test kits for stomach ulcers and upper respiratory infections. Meridian's Life Science division also rebounded from a weak Q1 in which the segment's operating income amounted to only $19,000. That amount compares unfavorably with the $848,000 the segment generated in operating income in the most recent quarter.
Management continues to seek out potential acquisition opportunities and prides itself on new-product innovation. For instance, in February, the company received FDA clearance for its new E. coli infection test. The test, the first of its kind, can differentiate between toxin 1 and toxin 2 types of E. coli and will be highly useful to hospitals in light of recent national E. coli outbreaks in the United States. With these innovations in mind, I believe that the company can maintain a high degree of growth.
Looking for that next breakout small cap? Try our market-beating Motley Fool Hidden Gems newsletter free for 30 days. Lead analyst Tom Gardner will give you two new picks this Thursday at noon.